Gabapentin ( DrugBank: Gabapentin )


5 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease1
13Multiple sclerosis/Neuromyelitis optica4
19Lysosomal storage disease1
70Spinal stenosis3
298Hereditary pancreatitis2

6. Parkinson disease


Clinical trials : 2,307Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

19. Lysosomal storage disease


Clinical trials : 899Drugs : 684 - (DrugBank : 99) / Drug target genes : 51 - Drug target pathways : 182 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

70. Spinal stenosis


Clinical trials : 95Drugs : 169 - (DrugBank : 61) / Drug target genes : 68 - Drug target pathways : 90 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

298. Hereditary pancreatitis


Clinical trials : 95Drugs : 148 - (DrugBank : 51) / Drug target genes : 53 - Drug target pathways : 142 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries